Want to see HAE full AI Analyst Report?
HAE Stock Chart & Stats
$105.00
$1.13(1.43%)
At close: 4:00 PM EDT
$105.00
$1.13(1.43%)
Day’s Range― - ―
52-Week Range$48.98 - $123.77
Previous Close$79.91
Volume803.18K
Average Volume (3M)680.09K
Market Cap
$5.33B
Enterprise Value$4.48B
Total Cash (Recent Filing)$223.38M
Total Debt (Recent Filing)$1.17B
Price to Earnings (P/E)56.8
Beta0.43
Next Earnings
Nov 05, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding45,497,050
10 Day Avg. Volume912,227
30 Day Avg. Volume680,087
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit5.78
Enterprise Value/Ebitda17.16
Forecast
1Y Price Target
$125.38Price Target Upside19.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.31
Revenue Forecast (FY)$1.42B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelHaemonetics’ equipment placements create an installed base that drives repeat purchases of proprietary disposables as collection procedures continue. This consumables-led model can support recurring revenue, customer retention and cash generation, while software and services add workflow integration over the medium term.
Strong Cash GenerationStrong operating and free cash flow gives Haemonetics capacity to fund product investment, support customer deployments and reduce debt without relying solely on external financing. Although conversion has varied historically, current cash generation provides a meaningful foundation for execution over the next several quarters.
Expanded CSL Plasma OpportunityThe CSL Plasma agreement could materially expand Haemonetics’ installed base and recurring disposable demand across U.S. collection centers. The anticipated rollout strengthens market presence and validates Persona PLUS adoption, although scope, timing and implementation remain subject to change.
Bears Say
Elevated LeverageThe materially higher debt burden reduces financial flexibility compared with prior years and can constrain capital allocation if earnings soften. Leverage also increases sensitivity to interest costs and makes debt reduction an important requirement for preserving resilience during the next several quarters.
Profitability ModerationLower net and operating margins indicate that recent revenue is converting into less profit than in the prior year. Sustained cost or mix pressure could limit earnings growth even if sales expand, reducing internal funding capacity and making margin recovery important to the medium-term outlook.
External Cost PressureExternal inflation, transportation and material pressures can continue to weigh on gross and operating margins after the temporary tariff refund is absorbed. This creates execution risk because management must offset cost increases through pricing, productivity or mix while maintaining investment in growth.
Haemonetics News
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $48.98 and its highest was $123.77 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $5.33B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 06, 2026. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.077 by $0.063.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.29.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 45,497,050 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.14 in its last earnings report, beating expectations of $1.077. Following the earnings report the stock price went up 1.699%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$125.38 (19.40% Upside)
$125.38 (19.40% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 60%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 42.3%
Last 30 Days ▲ 42.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
128.77%
12-Months-Change
Fundamentals
Return on Equity
11.35%
Trailing 12-Months
Asset Growth
-3.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Haemonetics Corp.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated broad‑based operational momentum: solid revenue and EPS growth, strong performance across core platforms (notably Plasma/Persona PLUS, Hemostasis, and Vascular Closure), upgraded fiscal guidance, and exceptional cash generation and debt paydown activity. Offsetting items include near‑term margin compression from prior‑year software recognition and sequential MedSurg revenue timing, higher operating costs, some OEM/ensoETM weakness in IVT, and continued external inflation/FX/headwind risks. Management emphasized disciplined, conservative guidance and prioritized deleveraging while keeping optionality for share repurchases and organic investment.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$125.38
▲(19.40% Upside)
Technical Analysis
Ownership Overview
1.82% Insiders
38.40% Mutual Funds
2.42% Other Institutional Investors
28.59% Public Companies and
Individual Investors